Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-03-20 07:30 |
Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published …
|
English | 75.7 KB | ||
| 2024-03-20 07:30 |
Nicox : Publication de résultats de l’étude de phase 3 Mont Blanc sur le NCX 47…
|
French | 102.7 KB | ||
| 2024-03-13 07:30 |
Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a…
|
English | 87.1 KB | ||
| 2024-03-13 07:30 |
Nicox fait le point sur les perspectives de son développement, de son portefeui…
|
French | 118.3 KB | ||
| 2024-03-05 07:30 |
Nicox : Présentation de données sur le NCX 470 au Congrès Annuel 2024 de l’Amer…
|
French | 93.7 KB | ||
| 2024-03-05 07:30 |
Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma S…
|
English | 90.1 KB | ||
| 2024-03-01 17:45 |
Nombre de droits de vote au 29 février 2024
|
French | 120.4 KB | ||
| 2024-03-01 17:45 |
Number of voting rights as of February 29, 2024
|
English | 121.1 KB | ||
| 2024-02-28 07:30 |
Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO
|
English | 206.1 KB | ||
| 2024-02-28 07:30 |
Gavin Spencer, dirigeant expérimenté du secteur de la biotechnologie, nommé Dir…
|
French | 284.3 KB | ||
| 2024-02-08 07:30 |
Nicox : Contrat de licence avec la société Kowa pour le développement et la com…
|
French | 80.0 KB | ||
| 2024-02-08 07:30 |
Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercializati…
|
English | 76.1 KB | ||
| 2024-02-06 07:30 |
Nicox announces presentations at the upcoming Association for Research in Visio…
|
English | 69.3 KB | ||
| 2024-02-06 07:30 |
Nicox : Présentations au prochain Congrès Annuel 2024 de l’Association for Rese…
|
French | 95.2 KB | ||
| 2024-02-01 17:45 |
Number of votings rights as of January 31 2024
|
English | 119.9 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
